In response to a request from the Commission, the European Medicines Agency (EMA) provided on 8 September 2021 a scientific analysis on the technical purpose of the use of titanium dioxide (E 171) in medicinal products, the feasibility of replacement and possible timeframes for alternatives. In its conclusions, EMA indicated that titanium dioxide is mainly used in medicinal products as a colour and opacifier, even if it has multiple functions. It also stressed that titanium dioxide is used frequently in a number of essential medicinal products in oral-solid and oral semi-solid dosage forms. EMA also stressed that, from a technical point of view, it should be possible to find alternatives to replace titanium dioxide (E 171)-containing coatings, both as colour and for other uses. However, it also underlined that its feasibility is not confirmed at this stage, as replacing titanium dioxide (E 171) would impact in a negative manner the quality, safety and efficacy of medicinal products. EMA highlighted the need to carefully assess alternatives, notably to ensure their compatibility with the various components of individual pharmaceutical products. The replacement of titanium dioxide (E 171) in authorised medicinal products would require an individual review and assessment, possibly requiring bioequivalence studies. Furthermore, EMA concluded that it is difficult at this stage to recommend a precise transition period timeframe for the replacement of titanium dioxide (E 171) used in medicinal products, as the time needed to reformulate each individual product could take several years, depending on the complexity of reformulation and studies required. Finally, considering the scale of the use of this excipient and the volume of products impacted, and taking into account global supply chains, EMA stressed that a requirement to replace titanium dioxide (E 171) would almost certainly cause significant medicines shortages on the Union market.
Recital 15, Regulation (EU) 2022/63
In forcesince 14 Jan 2022